SCP Mesh weight 75 performed an additional analysis for the subtypes of implants used, but did not find a significant difference in occurrence of graft-related complications between subtypes of heavier-weight and lightweight implants, respectively (heavier weight: 21.0% [4/19] for Marlex, 26.1% [11/42] for Prolene and 20.0% [8/40] for Gynemesh (p=.881); lightweight: 9/130 [6.9%] for Ultrapro and 4/48 [8.3%] for Artisyn; p= .885). Figure 1. Flow diagram of the study *Patients declined mainly due to fear of corona virus disease 2019 (COVID-19) and secondly due to social and health-related problems associated with elderly age. †Died of causes unrelated to surgery according to records and through contact with the general practitioner. Table 2. Patient characteristics Heavier Weight (n=101) Lightweight (n=238) p-value Age (years) 63.1 (8.7) 65.1 (11.5) 0.121 BMI (kg/m2) 26.1 (3.6) 25.7 (3.8) 0.323 Diabetes 4 (4.0) 22 (9.2) 0.119 Smoking 14 (13.9) 23 (9.7) 0.234 Parity 2 (0-7) 2 (0-6) 0.111 ≥1 instrumental deliveries 16 (15.8) 18 (7.6) 0.200 ≥1 children with birth weight >4000gr 27 (26.7) 50 (16.8) 0.313 Menopause 95 (94.1) 214 (89.9) 0.065 Hormone therapy* 30 (29.7) 40 (16.8) 0.012 Sexually active 64 (65.3) 128 (57.9) 0.214 Prior prolapse surgery* 84 (83.2) 164 (68.9) 0.008 Prior hysterectomy*† 92 (91.1) 146 (61.3) <0.0001 Concomitant supracervical hysterectomy*‡ 10 (9.9) 84 (35.3) <0.0001 Concomitant incontinence surgery 3 (2.9) 16 (6.7) 0.169 Concomitant rectopexy 5 (4.9) 4 (1.7) 0.087 Follow-up (months)* 97 (72-163) 92.5 (13-163) <0.001 *significant difference between groups. †all previous hysterectomies were total. ‡ in case of concomitant hysterectomy these were all performed subtotal; Data are reported as Mean (SD), number (%), median (range); Continuous variables were analyzed with t test, categorical data with χ2 Fisher exact.
RkJQdWJsaXNoZXIy MTk4NDMw